3 Biotech Stocks Under $3 With 200%-Plus Upside Potential
Solid Biosciences: Keep Your Eyes On The Prize Says Top Analyst
Seres Therapeutics Reports Weak Earnings, But Significant Upside Lies Ahead
Coronavirus Vaccine Could Add Massive Value to This Small-Cap Stock, Says Analyst
Ex-AstraZeneca exec Kristen Buck hops aboard Icon as CMO; Immunocore taps Brian DiDonato as CFO
Two years after a wrenching setback, Protagonist touts a slice of data and sets sights on pivotal trial in a surprising place: the blood
3 Healthcare Stocks Under $6 That Could More Than Double: Wedbush
3 Biotech Stocks Under $6 That Could More Than Double: Wedbush
Capricor (CAPR) Shares Could Hit $10, Says Analyst
Analyst Believes Potential COVID-19 Treatment Can Push Ahersys (ATHX) Stock up to $12
AstraZeneca's blockbuster Farxiga secures landmark approval in heart failure patients, regardless of whether they have diabetes
3 "Strong Buy" Biotech Stocks Trading Under $10
Drugmaker Eli Lilly Partners With China’s Junshi For Covid-19 Antibody Treatment
Newron's Merck KGaA-in licensed compound fails Rett Syndrome study, shares wilt
Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 30%
SFU professor’s invention approved by FDA to help wean COVID-19 patients from ventilators
High-profile R&D specialist David Lebwohl jumps to new job as CMO of a pioneering CRISPR player; Troubled AMAG Pharmaceuticals taps Scott Myers as CEO
Troubled AMAG Pharmaceuticals taps Scott Myers as CEO and president; Cheryl Blanchard secures CEO title at Anika Therapeutics